Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside evidence based clinical assessments and investment research on pipeline drugs worldwide.
This report combines data from Medtrack with anonymized data from BIO-Europe to identify key trends related to partnering to help you better understand the state, and the power, of collaboration.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
By Dustin Phan
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Pharmaprojects: track pharma R&D, Biomedtracker: see the dru...
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: